# Oral Nitrite Trial for Hypertension and Metabolic Syndrome

> **NCT02517697** · PHASE2 · WITHDRAWN · sponsor: **Gladwin, Mark, MD**

## Conditions studied

- Metabolic Syndrome
- Hypertension

## Interventions

- **DRUG:** 14 Nitrogen (N) Sodium Nitrite
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02517697
- **Lead sponsor:** Gladwin, Mark, MD
- **Sponsor class:** INDIV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-10
- **Primary completion:** 2021-04-13
- **Final completion:** 2021-04-13
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** We will not initiate recruitment for this protocol due to lack of funding to support this placebo-controlled trial.
- **Last updated:** 2021-04-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02517697

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02517697, "Oral Nitrite Trial for Hypertension and Metabolic Syndrome". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02517697. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*